Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone.
Mitoxantrone was used as an immunosuppressive probe to elucidate a means for the control of experimental allergic encephalomyelitis (EAE) induced in Biozzi AB/H mice following injection of spinal cord homogenate emulsified in Freund's adjuvant. A single i.p. injection of 2.5 mg/kg of mitoxantrone, 1-2 days before the anticipated onset of EAE, failed to prevent the majority of animals from developing clinical disease, whereas when the compound was injected directly into the central nervous system (CNS), at this time point, significantly increased therapeutic benefit was evident, with most animals failing to develop clinical EAE. Although the clinical use of intrathecal mitoxantrone is strongly contraindicated, these data suggest that increased therapeutic benefit may be achieved in immune-mediated disease of the CNS by targeting immunosuppressive doses of suitable agents, on lymphocyte activation within the CNS. In addition, direct administration of immunosuppressive doses into the CNS may reduce potentially unwanted (side) effects in the periphery.
Baker
D
D
Department of Pathology, Royal College of Surgeons of England, London, UK.
O'Neill
J K
JK
Davison
A N
AN
Turk
J L
JL
D000818:Animals; D001812:Blood-Brain Barrier; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007276:Injections, Intraventricular; D051379:Mice; D008815:Mice, Inbred Strains; D008942:Mitoxantrone / Q000008:administration & dosage / Q000494:pharmacology*
D007166:Immunosuppressive Agents; D008942:Mitoxantrone